Fresh Tracks Therapeutics, Inc. (FRTX)
(Delayed Data from OTC)
$0.95 USD
+0.03 (3.26%)
Updated Jul 12, 2024 01:28 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
FRTX 0.95 +0.03(3.26%)
Will FRTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for FRTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FRTX
Fresh Tracks Therapeutics (FRTX) Reports Q3 Loss, Tops Revenue Estimates
FRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for FRTX
Fresh Tracks Therapeutics Announces Delaware Petition Filed Seeking Appointment of Custodian for Eventual Dissolution of Company
Monopar Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying
Clover Health Investments And 2 Other Stocks Under $1 Insiders Are Buying